These trials have consistently demonstrated the role of GLP-1 RAs in reducing major adverse cardiovascular events (MACE), non-fatal myocardial infarction, non-fatal stroke, and composite heart failure events. The gene discussed is GLP1R; the disease is myocardial infarction.